Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSTERITY: Obinutuzumab in Adolescent and Pediatric Lupus Nephritis
NCT05039619Phase 2Recruiting
- Sponsor
- Roche
- Start
- May 2022
- Primary completion
- Jun 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of obinutuzumab in lupus nephritis (LN), sponsored by Roche. Started May 2022; status: recruiting.
02
Drugs
obinutuzumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05039619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05039619.